Melissa Rhodes, Chief Operating Officer of Avalyn Pharma Inc., filed a Form 4 on November 19, 2026, disclosing the exercise of stock options and the sale of 13,300 shares of common stock on November 17, 2026, pursuant to a Rule 10b5-1 trading plan.
Key Highlights
- Option exercise: Rhodes exercised stock options covering 13,300 shares of common stock at an exercise price of $4.62 per share on November 17, 2026.
- Shares sold: All 13,300 acquired shares were sold across three tranches on the same date, resulting in zero directly held common shares following the transactions.
- Sale prices: The three tranches carried weighted average prices of $27.7918, $28.2069, and $29.2286, with individual transaction prices ranging from $27.10 to $29.37 across all tranches.
- 10b5-1 plan: According to the filing, all transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on July 30, 2026.
- Remaining derivative holdings: Following the transactions, Rhodes beneficially owned 170,638 stock options (right to buy) with an exercise price of $4.62 and an expiration date of January 24, 2034.
Rhodes Option Exercise and Sale Details at Avalyn Pharma
According to the Form 4 filed with the SEC on November 19, 2026, Melissa Rhodes, Chief Operating Officer of Avalyn Pharma Inc. (NASDAQ:AVLN), exercised stock options covering 13,300 shares of common stock at $4.62 per share on November 17, 2026. The filing states that this transaction, coded "M," reduced her outstanding options by 13,300 shares, leaving 170,638 stock options beneficially owned directly following the reported transactions.
The filing further discloses that Rhodes sold all 13,300 of the acquired shares on the same date in three separate sale transactions, each coded "S." The first tranche of 10,875 shares was sold at a weighted average price of $27.7918, with individual prices ranging from $27.10 to $28.09. The second tranche of 2,025 shares was sold at a weighted average price of $28.2069, with individual prices ranging from $28.10 to $28.93. The third tranche of 400 shares was sold at a weighted average price of $29.2286, with individual prices ranging from $29.11 to $29.37. After these three sales, the filing reports that Rhodes held zero shares of common stock directly.
The filing notes that the stock options subject to the exercise vest 25% on September 11, 2024, with the remaining 75% vesting in 36 substantially equal monthly installments thereafter, subject to the reporting person's continued service on each vesting date. The filing was signed by Douglas Carlson as Attorney-in-Fact on November 19, 2026. The box indicating a Rule 10b5-1(c) compliant plan is checked on the form.
What Was Disclosed
Melissa Rhodes, COO of Avalyn Pharma Inc., disclosed the exercise of 13,300 stock options at $4.62 and the same-day sale of all resulting shares at weighted average prices between $27.7918 and $29.2286, all under a Rule 10b5-1 plan adopted July 30, 2026.



Please wait processing your request...